Living macrophage-based drug promotes antitumor immunotherapy

Persistent pupillary membrane
18 January 2021
It’s crucial we address COVID vaccine hesitancy among health workers. Here’s where to start
18 January 2021

Living macrophage-based drug promotes antitumor immunotherapy

Immunotherapy is one of the most promising approaches to inhibit tumor growth and metastasis by activating host immune functions. However, so far, immunotherapy still exhibits limitations of efficacy and safety, such as huge individual differences in treatment responses, difficulty to work on solid tumors, systemic immune storm and other immunotoxicity.

Comments are closed.